Garrett C. Moraski, B.S.
Affiliations: | 1997-2001 | Oncology | Pfizer Inc |
| 2001-2002 | Oncology | Array Biopharma, Inc. | |
| 2002-2004 | Drug Discovery | Thios Pharmaceuticals | |
| 2004-2012 | Chemistry and Biochemistry | University of Notre Dame, Notre Dame, IN, United States | |
| 2012-2013 | Infectious Dieases | SRI International, Menlo Park, CA, United States | |
| 2013- | Chemistry and Biochemistry | Montana State University, Bozeman, MT |
Area:
Medicinal Chemistry, Tuberculosis, AntibacterialWebsite:
http://www.chemistry.montana.edu/directory/1908864/garrett-moraskiGoogle:
"Garrett Moraski"Bio:
Worked with Joseph P. Lyssikatos at Pfizer, Array and Thios leading to the disovery of multiple clinical candidates, including Crenolanib.
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Marvin J. Miller | research scientist | 2004-2012 | Notre Dame | |
| (Also undergraduate student of Prof. Miller) | ||||
Children
Sign in to add trainee| Sarah Hopfner | grad student | 2015- | Montana State |
| Kate Marshall | post-doc | 2019- | Montana State |
| Samuel Bernhard | post-doc | 2020- | Montana State |
| Juliana R. Alexander | post-doc | 2018-2019 | Montana State |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu R, Marshall K, Ma R, et al. (2022) Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties. Bioorganic Chemistry. 128: 106074 |
| Hopfner SM, Lee BS, Kalia NP, et al. (2021) Syntheses and Structure-Activity Relationships of -Phenethyl-Quinazolin-4-yl-Amines as Potent Inhibitors of Cytochrome Oxidase in . Applied Sciences (Basel, Switzerland). 11 |
| Sorayah R, Moraski GC, Barkan D, et al. (2021) The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 65: e0096421 |
| Hopfner SM, Lee BS, Kalia NP, et al. (2021) Structure guided generation of thieno[3,2-]pyrimidin-4-amine oxidase inhibitors. Rsc Medicinal Chemistry. 12: 73-77 |
| Liu R, Markley L, Miller PA, et al. (2021) Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds. Rsc Medicinal Chemistry. 12: 62-72 |
| Lee BS, Hards K, Engelhart CA, et al. (2020) Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. Embo Molecular Medicine. e13207 |
| Moraski GC, Deboosère N, Marshall KL, et al. (2020) Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. Plos One. 15: e0227224 |
| Kalia NP, Shi Lee B, Ab Rahman NB, et al. (2019) Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc:aa in Mycobacterium tuberculosis. Scientific Reports. 9: 8608 |
| Scherr N, Bieri R, Thomas SS, et al. (2018) Targeting the Mycobacterium ulcerans cytochrome bc:aa for the treatment of Buruli ulcer. Nature Communications. 9: 5370 |
| O'Malley T, Alling T, Early JV, et al. (2018) Imidazopyridine compounds inhibit mycobacterial growth by depleting ATP levels. Antimicrobial Agents and Chemotherapy |